Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin
LAMIRA®, an eFlow® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union
PARI's optimized Investigational eFlow® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
